British researchers say they have found new clues to the side effects faced by some patients who take statins.
The study, undertaken at Warwick University, shows that the drugs interact with a protein called GJC3. This releases ATP, a signalling molecule for inflammation in the body.
The researchers say this is a "significant new target" in the search to explain why statins can cause muscle toxicity in some patients.
Researcher Dr Andrew Marsh said: “Statins are powerful cholesterol-lowering medicines that are widely prescribed to reduce the burden of cardiovascular disease. Gap junction proteins are important in forming communication channels between cells and organs in the body.
"In this new research, two clinically used statin therapeutics have been found to interact with an important part of GJC3, a gap junction protein which acts to release ATP, a signalling molecule that is key to the body’s response to injury and inflammation.
“Many people know ATP as the cell’s main energy transfer molecule, but when released outside cells, ATP coordinates how tissues including our liver and muscles deal with recovery from injury.
"These results may give us better understanding of how some of the harmful effects of statins in some patients, such as muscle toxicity, might come about."
He added: “GJC3 is present in many tissues in the body, but its role in cell signalling is poorly understood. Our work opens doors to its investigation."
Fellow researcher Professor Donald Singer said: “Finding additional ways in which statins act at the cellular and molecular level is important for giving clues to potential new medical applications for these drugs.
"These results may also give us better understanding of how some of the harmful effects of statins in some patients might come about."
Professor Donald Singer et al.; Simvastatin sodium salt and fluvastatin interact with human gap junction gamma-3 protein; PLOS ONE manuscript PONE-D-13-07792R2; 10 Feb 2016

Leave a Reply